成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

3-巖藻糖基乳糖,3-Fucosyllactose
  • 3-巖藻糖基乳糖,3-Fucosyllactose
  • 3-巖藻糖基乳糖,3-Fucosyllactose
  • 3-巖藻糖基乳糖,3-Fucosyllactose
  • 3-巖藻糖基乳糖,3-Fucosyllactose

3-FL3-巖藻糖基乳糖是人乳寡糖中常見的一種主打

價(jià)格 1538 3900 6380
包裝 10mg 50mg 100mg
最小起訂量 10mg
發(fā)貨地 上海
更新日期 2024-12-25
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:3-巖藻糖基乳糖英文名稱:3-Fucosyllactose
CAS:41312-47-4品牌: Glycarbo
產(chǎn)地: 進(jìn)口保存條件: 2-8°C
純度規(guī)格: ≥98%產(chǎn)品類別: 糖化學(xué)分析標(biāo)準(zhǔn)品
貨號(hào): GY1142 GY1142M用途范圍: 科研分析,原料
規(guī)格: 10mg 50mg 100mg 1g是否進(jìn)口:
其他產(chǎn)品: 2-巖藻糖基乳糖(2FL)現(xiàn)貨
2024-12-25 3-巖藻糖基乳糖 3-Fucosyllactose 10mg/1538RMB;50mg/3900RMB;100mg/6380RMB 1538 Glycarbo 進(jìn)口 2-8°C ≥98% 糖化學(xué)分析標(biāo)準(zhǔn)品

Cat. Number
GY1142
Chemical Name
3-巖藻糖基乳糖 3-FL/3-Fucosyllactose
CAS Number
41312-47-4
Category
Oligosaccharides
Mol. Formula
C18H32O15
Mol. Weight
488.44
Qty 1
10mg
Qty 2
25mg
Appearance
White - slightly brown, powder
Application Notes
≥98%
Synonym
Galβ1-4(Fucα1-3)Glc
Storage condition
2-8°C
Stability
2 years
References

HMO是一類獨(dú)特的、天然存在于母乳中的碳水化合物,包含2’-Fucosyllactose,3'-Fucosyllactose

人乳寡糖HMOs系列,Human Milk Oligosaccharides

人乳寡糖Human Milk Oligosaccharides是一類自然存在于人乳中的復(fù)雜混合低聚糖,上?;菡\生物提供人乳寡糖(HMOs)系列產(chǎn)品

3'-Fucosyllactose
41312-47-4
C18H32O15
488.44
2’-Fucosyllactose
41263-94-9
C18H32O15
488.44
6'-Sialyllactose
56144-12-8
C23H39NO19
633.55
3'-Sialyllactose
35890-38-1
C23H39NO19
633.55
Lacto-N-tetraose
14116-68-8
C26H45NO21
707.63
Lacto-N-neotetraose
13007-32-4
C26H45NO21
707.63
Lacto-N-fucopentaose I
7578-25-8
C32H55NO25
853.77
Lacto-N-fucopentaose II
21973-23-9
C32H55NO25
853.77
Lacto-N-fucopentaose III
25541-09-7
C32H55NO25
853.77
Lacto-N-fucopentaose V
60254-64-0
C32H55NO25
853.77

上?;菡\生物提供人乳寡糖系列產(chǎn)品,更多寡糖,多糖產(chǎn)品,請(qǐng)聯(lián)系021-60498804,我們竭誠為您提供各類糖產(chǎn)品。 

3'-Sialyl-3-fucosyllactose

Human Milk Oligosaccharides系列

 

Human breast milk provides the primary source of nutrition for newborns before they are able to eat and digest other foods. One distinctive property of human milk from most other species is the amount and diversity of the free oligosaccharide it contains. These human milk oligosaccharides (HMO) can be present at levels of up to 12 g/l in milk and up to 20 g/l in colostrum.1 HMO have been attributed with a variety of functions including:

1) Prebiotic
2) Decoy carbohydrate
3) Immunomodulation

HMO Structure
Currently at least 130 unique HMO have been identified, all differing by constituent sugars, molecular weight or structure. Many share a common motif characterized by repetitive attachment of galactose (Gal) and N-acetylglucosamine (GlcNAc)in a b-glycosidic linkage to lactose. Additional variety is generated by the addition of fucose (termed neutral HMO), e.g. 3'-Fucosyllactose, (05673) or 2-Fucosyllactose, (06739) and sialic acid (termed acidic HMO), e.g. 6'-Sialyllactose, (04398) and 3'-Sialyllactose, (04397). Addition is via a-glucosidic bonds to generate oligosaccharides from three to thirty two sugars in length. Whilst most of the biosyntheis of HMO is not controlled at the gene level (unlike proteins) the presence and position of fucosylation is governed by the Lewis/Secretor status of the mother.3
Dominant neutral oligosaccharides have been identified as lacto-N-tetraose (05683), lacto-N-neotetraose (05765) and lacto-N-fucopentaose I and V (05676 and 06817 respectively)4

Prebiotic Properties of HMO
The most abundant HMO is lacto-N-tetraose which is able to survive the acid environment of the stomach and is not degraded by normal gut enzymes. It therefore can pass down to the lower intestine where it acts as a prebiotic which encourages lower gut colonisation by many bi?dobacteria species, which are recognised as essential for normal gut function.5

HMO as Decoy Carbohydrates
Binding to a host cell wall is critical for the virulence of many pathogenic bacteria including Campylobacter jejuni, E.coli, Vibrio cholera, and Shigella and some Salmonella strains. Many of the virulence factors of these organisms are carbohydrate-binding proteins (lectins) which bind sugars displayed on cell membranes. HMO can bind to these lectins acting as decoys and preventing pathogens from sticking to the target cells. An example of this is the inverse relationship between the incidence of C. jejuni, (one of the most predominant causes of diarrhoea in the world) in breast-fed children and levels of 2-fucosyl-lactose in the mother’s milk. (C. jejuni is known to adhere to intestinal 2-fucosyl-lactosamine).6 Similar antimicrobial effects of HMO have also been demonstrated for calicivirus diarrhoea and infections with heat stable enterotoxin of E. coli.7
During ingestion, HMO coat the throat and are known to inhibit adhesion of Streptococcus pneumoniae and Haemophilus in?uenzae to human pharyngeal or buccal epithelial cells resulting in the lower incidence of otitis media (inner ear infection) in breast fed babies.8

Immune Role of HMO
Selectins are glycoproteins which are displayed on the surface of many cells of the immune system and are involved with cell/cell interactions such as the infiltration of tissues in inflammation. Selectins bind to specific fucosylated and sialylated oligosaccharides, e.g., sialyl Lewis x (sLex, 04058), on their respective target ligands. HMO share many structural similarities to these carbohydrate ligands and acidic (sialylated) HMO are able to inhibit rolling and adhesion of leucocytes at physiologically relevant concentrations.
One of these selectin interactions is the formation of platelet/neutrophil complexes (PNCs) which lead to the activation of the neutrophils. PNCs are thought to be involved in necrotizing enterocolitis (NEC) and HMO have been attributed as the agent responsible for the lower incidence of NEC in breast fed infants (85 % lower than formula fed infants) via inhibition of PNC formation.9
Fractions of HMO are also known to inhibit the binding of both Galectins which bind b-Gal and LAcNAc terminated glycans and Siglecs which are specific for terminal sialic acid, their role in immunity or development however has not yet been fully explored.10,11





關(guān)鍵字: 3-FL;巖藻糖基乳糖;41312-47-4;3-巖藻糖基乳糖;41312-47-4;

公司簡(jiǎn)介

上海惠誠生物科技有限公司,成立于2010年,企業(yè)宗旨“惠質(zhì)產(chǎn)品,摯誠服務(wù)”。惠誠生物自成立以來,一直致力于為客戶提供一站式科學(xué)服務(wù),產(chǎn)品覆蓋設(shè)計(jì)開發(fā)全過程,提供實(shí)驗(yàn)室設(shè)計(jì)、實(shí)驗(yàn)室建設(shè)、儀器設(shè)備、耗材、試劑、技術(shù)服務(wù)等專項(xiàng)配套服務(wù), 按照客戶的研發(fā)、生產(chǎn)和質(zhì)量控制環(huán)節(jié)整合各種優(yōu)質(zhì)資源,優(yōu)化資源組合,為客戶提供最具價(jià)值的整體解決方案?;菡\生物在上海建立研發(fā)中心,在湖北和江蘇有生產(chǎn)基地,在廣州和深圳建立子公司,立足上海,銷售網(wǎng)絡(luò)遍布全國,為客戶提供全方位的綜合服務(wù)。 “不忘初心,砥礪前行”?;菡\生物經(jīng)過多年不懈努力,目前產(chǎn)品線包括:生命科學(xué),分析化學(xué),生化試劑和儀器耗材??蛻舯椴迹荷镝t(yī)藥,體外診斷,食品行業(yè),石油化工,科研院校和研究所等領(lǐng)域。 上?;菡\生物科技有限公司,成立于2010年,企業(yè)宗旨“惠質(zhì)產(chǎn)品,摯誠服務(wù)”。惠誠生物自成立以來,一直致力于為客戶提供一站式科學(xué)服務(wù),產(chǎn)品覆蓋設(shè)計(jì)開發(fā)全過程,提供實(shí)驗(yàn)室設(shè)計(jì)、實(shí)驗(yàn)室建設(shè)、儀器設(shè)備、耗材、試劑、技術(shù)服務(wù)等專項(xiàng)配套服務(wù), 按照客戶的研發(fā)、生產(chǎn)和質(zhì)量控制環(huán)節(jié)整合各種優(yōu)質(zhì)資源,優(yōu)化資源組合,為客戶提供最具價(jià)值的整體解決方案?;菡\生物在上海建立研發(fā)中心,在湖北和江蘇有生產(chǎn)基地,在廣州和深圳建立子公司,立足上海,銷售網(wǎng)絡(luò)遍布全國,為客戶提供全方位的綜合服務(wù)。 “不忘初心,砥礪前行”?;菡\生物經(jīng)過多年不懈努力,目前產(chǎn)品線包括:生命科學(xué),分析化學(xué),生化試劑和儀器耗材。客戶遍布:生物醫(yī)藥,體外診斷,食品行業(yè),石油化工,科研院校和研究所等領(lǐng)域。
成立日期 2010-08-16 (15年) 注冊(cè)資本 50
員工人數(shù) 10-50人 年?duì)I業(yè)額 ¥ 500萬-1000萬
主營行業(yè) 化學(xué)試劑,通用試劑,中草藥提取物 經(jīng)營模式 貿(mào)易,試劑,服務(wù)
  • 上?;菡\生物科技有限公司
VIP 5年
  • 公司成立:15年
  • 注冊(cè)資本:50
  • 企業(yè)類型:有限責(zé)任公司
  • 主營產(chǎn)品:生物試劑和標(biāo)準(zhǔn)品,包括:細(xì)胞因子,Crispr/cas酶, 診斷蛋白,糖化學(xué),脂肪酸,花青素,類胡蘿卜素,人乳寡糖等
  • 公司地址:上海市徐匯區(qū)漕溪路258弄27號(hào)
詢盤

3-FL3-巖藻糖基乳糖是人乳寡糖中常見的一種相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
VIP7年
上海祥耕科技發(fā)展有限公司
2024-12-24
詢價(jià)
VIP1年
陜西西化化學(xué)工業(yè)有限公司
2024-12-17
¥17500
VIP3年
TargetMol中國(陶術(shù)生物)
2024-12-12
詢價(jià)
VIP5年
武漢糖智藥業(yè)有限公司
2024-03-22
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的